Although the numbers were scary, they weren't shocking — they were expected. Around half of AstraZeneca's sales declines stemmed from the loss of patent exclusivity for drugs. Arimidex, Atacand, Crestor, Nexium, Seroquel IR and Seroquel XR all experienced revenue drops, due partially to generic competition — although only in parts of the world for some of the drugs.